Daily Clinical Briefing · Educational reading for healthcare professionals
GRADE helps distinguish promising research findings from evidence reliable enough to guide clinical decisions.
Before applying a trial, check its comparator and outcomes: evidence against placebo may not answer a choice between two active treatments.
An older patient needs to choose between two active treatments. A published study looks promising. It includes patients of a similar age, uses the treatment being considered and reports a favourable result.
There is a problem, though. The study compares the treatment with placebo and measures laboratory markers. The patient wants to know which of the two available treatments will improve their quality of life.
The research may be perfectly reasonable, but it does not directly answer the clinical question.
This is what GRADE describes as indirectness. It is one of five domains used to judge certainty in evidence, alongside risk of bias, imprecision, inconsistency and publication bias.
We often think about applicability in terms of whether the patients in a study resemble those we treat. That is only one part of it. The population, intervention, comparator and outcome all matter. A study can recruit exactly the right patients and still provide indirect evidence because it measures the wrong outcome or compares against the wrong treatment.
Then there is the confidence interval.
A trial may report an effect estimate favouring treatment. That looks encouraging until the confidence interval is examined and found to include no effect, clinically important benefit and clinically important harm.
The point estimate has not changed, but our confidence in the result should. This is imprecision. It tells us that the available evidence cannot distinguish reliably between outcomes that would lead to very different clinical decisions.
Inconsistency is different. When several studies addressing the same question produce substantially different effects, we need to understand why before combining their findings into a recommendation.
Risk of bias concerns how the studies were conducted. Selection, measurement and confounding are particularly relevant to observational research. Blinding, dropout and selective reporting deserve attention in randomised trials. Publication bias raises another difficult question: what studies might be missing from the published evidence altogether?
The distinction between an interesting finding and reliable evidence is illustrated by the neurological research discussed today. Altered right parietal blood flow was reported in three patients with Alzheimer's disease and delusional companion syndrome. It is a finding worth investigating, but three patients cannot establish a definitive neurological localisation or prove the proposed hemispheric mechanism.
There is a final complication. Evidence changes. The newest study is not automatically the most reliable, but sufficiently important new research may justify revisiting a recommendation even immediately after a review has been completed.
Evidence-based medicine brings together research, clinical expertise and patient values. Before adopting a recommendation, establish whether the research answers the decision being made, how certain its findings are and whether its outcomes matter to the patient.
For the older patient choosing between two treatments, a favourable result against placebo may simply be insufficient to make that choice.
GRADE separates risk of bias, imprecision, inconsistency, indirectness and publication bias when assessing evidence certainty. Clinical decisions also require a relevant comparator, patient-important outcomes and consideration of whether new research genuinely changes existing recommendations.
Delusional companion syndrome involves an unusually strong sense of familiarity with an inanimate object believed to think and feel. It occurs across neurological and psychiatric conditions, while proposed hemispheric mechanisms and right parietal localisation remain supported by limited evidence.
Before using a study to support a clinical decision, identify the population, intervention, comparator and patient-important outcome. Check whether the confidence interval includes clinically important benefit or harm, and distinguish that uncertainty from disagreement between studies. When the evidence remains uncertain, explain its limitations alongside your clinical judgement and the patient's priorities.
A clinician is choosing between two active treatments for an older patient whose main priority is quality of life. A trial recruits an appropriate population and tests the intended intervention, but compares it with placebo and reports laboratory markers rather than quality of life. Which GRADE domain best describes the limitation?
Indirectness. The trial has mismatches in both its comparator and outcome. Even when the population and intervention are appropriate, evidence may be insufficiently direct to answer the clinical decision.
A randomised trial reports a treatment effect that favours an intervention. However, its confidence interval includes no effect, clinically important benefit and clinically important harm. Which aspect of evidence certainty is most affected?
Imprecision. The range of plausible treatment effects includes outcomes that would support substantially different clinical decisions. The favourable point estimate alone does not establish a reliable benefit.
A patient with a neurodegenerative disorder becomes strongly attached to a doll and believes it can think and experience feelings. The patient treats the doll as a genuine companion. Which delusional misidentification syndrome best describes this presentation?
Delusional companion syndrome. It involves hyperfamiliarity with an inanimate object and the belief that it can think and feel. The syndrome has been described in neurological, developmental and primary psychiatric disorders.
Daily Clinical Briefings are prepared using ChatGPT Pro from the show notes and educational output for that day’s episodes. Iain Beardsell then checks the briefing for accuracy.
This describes the current briefing process. Item-specific review dates are shown only where documented. The original podcasts remain the sources; MedPod’s briefing is additional educational material.
Read about MedPod’s editorial approach
Report an error or source concern — please include the article title and link, without patient-identifying information.
.svg)